Fig. 4
From: RGS5 maintaining vascular homeostasis is altered by the tumor microenvironment
SM22α acts additively and synergistically with RGS5 to suppress VSMC inflammation. (A) Western blot analysis and quantification of SM22α, RGS5 and macrophage-like markers (C3, CD74 and Lyz2) in WT and SM22α-KO VSMCs stimulated with TNFα for 0, 6, 12, 24 and 48 h, respectively. (B) Protein levels of SM22α, RGS5 and macrophage-like markers (C3, CD74 and Lyz2) in WT VSMCs transfected with si-Con (50 nM) or si-SM22α (50 nM). (C) Western blot analysis and quantification of RGS5 and macrophage-like markers (C3, CD74 and Lyz2) in SM22α-KO VSMCs transfected with RGS5-siRNA (si-Con or si-RGS5) or RGS5-lentivirus (Lenti-RGS5 or vector control) followed by TNF-α treatment. (D) Western blot analysis and quantification of SM22α, RGS5 and macrophage-like markers (C3, CD74 and Lyz2) in WT VSMCs transfected with Ad-GFP and Ad-SM22α with or without TNF-α stimulation. The data were presented as the mean ± SD